[The immunological validation and the potentials and prospects of using immunocorrective agents in treating hemoblastoses].

Immunocorrection was provided to 94 patients with hemoblastoses. Of these, 50 patients suffered from lymphogranulomatosis and 8 from acute leukemias. Levamisole (decaris, Hungary) and the Soviet drug tactivin were applied as immunocorrectors. The effects of levamisole and tactivin in chronic lymphoid leukemia are combined. They are related to immunologic differentiation of the cells. The patients showed an increase of the count of E-RFC, a decline of the B cell count with superficial immunoglobulins, Em-RFC, changes in the T mu: T gamma cell ratio, and the maintenance of the level of serum immunoglobulins. As a result of the continuous administration of immunocorrectors, there was a rise of the count of B cells with immunoglobulins in the cytoplasm. The continuous use of immunocorrectors favours stabilization of the course of the underlying disease, an increase of the patients' life expectancy. In patients with lymphogranulomatosis, the use of levamisole as part of the multimodality treatment leads to an increase of the count of E-RFC, augmentation of the life expectancy. The treatment with immunocorrectors should be carried out under control of the immunity parameters.